Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.92 USD
+0.30 (18.52%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.91 -0.01 (-0.52%) 7:56 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ESPR 1.92 +0.30(18.52%)
Will ESPR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ESPR
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
Other News for ESPR
Esperion Therapeutics Inc (ESPR) Q2 2025 Earnings Call Highlights: Strong US Net Product ...
Esperion Therapeutics (ESPR) Sees Revenue Surge, Eyes Profitability by 2026
Q2 2025 Esperion Therapeutics Inc Earnings Call Transcript
Esperion rises after revenue beat, Q1 profitability expectation
Esperion expects sustainable profitability in Q1 2026 as double-digit growth continues